D Merims

Summary

Country: Israel

Publications

  1. ncbi request reprint Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease
    D Merims
    Movement Disorders Unit, Department of Neurology, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    J Neural Transm 111:1447-53. 2004
  2. doi request reprint Subjective memory decline in healthy community-dwelling elders. What does this complain mean?
    Y Balash
    Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    Acta Neurol Scand 121:194-7. 2010
  3. ncbi request reprint The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches
    D Merims
    Department of Neurology, Rabin Medical Center, Belinson Campus, Petah Tikva
    Neurol Neurochir Pol 35:65-8. 2001

Collaborators

Detail Information

Publications3

  1. ncbi request reprint Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease
    D Merims
    Movement Disorders Unit, Department of Neurology, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    J Neural Transm 111:1447-53. 2004
    ..Accumulating evidence suggests the existence of other risk factors for psychosis in PD. Aims. To evaluate the contribution of the drug profile of patients with PD to emergence of hallucinations...
  2. doi request reprint Subjective memory decline in healthy community-dwelling elders. What does this complain mean?
    Y Balash
    Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    Acta Neurol Scand 121:194-7. 2010
    ..The causes of this are heterogeneous, and may be related to both affective and cognitive disorders. We attempted to explore the associations between subjective and cognitive measures...
  3. ncbi request reprint The role of glutamatergic transmission in the pathogenesis of levodopa-induced dyskinesias. Potential therapeutic approaches
    D Merims
    Department of Neurology, Rabin Medical Center, Belinson Campus, Petah Tikva
    Neurol Neurochir Pol 35:65-8. 2001
    ..Indeed, NMDA receptor antagonists such as amantadine and dextrometorphan can reduce such dyskinesias. We tested the efficacy of riluzole, an inhibitor of glutamatergic transmission in the inhibition of levodopa-induced dyskinesias...